In vivo studies on the oridonin-loaded nanostructured lipid carriers

Drug Delivery

Volumn 19, Issue 6, 2012, Pages 286-291

  Zheng, Dandan ^a   Dai, Wenting ^b   Zhang, Dianrui ^a   Duan, Cunxian ^a   Jia, Lejiao ^a   Liu, Yue ^a   Zhang, Qiang ^c  

^a SHANDONG UNIVERSITY   (China)

^b Second People's Hospital of Hefei   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Biodistribution; Intravenous administration; Nanostructured lipid carriers; Oridonin; Pharmacokinetics

Indexed keywords

LIPID; NANOMATERIAL; ORIDONIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RELEASE; EMULSION; EVAPORATION; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF QUANTITATION; LOW TEMPERATURE; MORPHOLOGY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; ZETA POTENTIAL;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; DITERPENES, KAURANE; DRUG DELIVERY SYSTEMS; EMULSIONS; LIPIDS; MICE; NANOPARTICLES; PARTICLE SIZE; TEMPERATURE; TISSUE DISTRIBUTION;

EID: 84866257716     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2012.704096     Document Type: Article

References (25)

1. Chen CC, Tsai TH, Huang ZR, Fang JY. (2010). Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm 74:474-482
2. Dai W, Zhang D, Duan C, Jia L, Wang Y, Feng F, Zhang Q. (2010). Preparation and characteristics of oridonin-loaded nanostructured lipid carriers as a controlled-release delivery system. J Microencapsul 27:234-241
3. Gao L, Zhang D, Chen M, Duan C, Dai W, Jia L, Zhao W. (2008). Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int J Pharm 355:321-327
4. Hsieh TC, Wijeratne EK, Liang JY, Gunatilaka AL, Wu JM. (2005). Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF- 7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens. Biochem Biophys Res Commun 337:224-231 (Pubitemid 41393783)
5. Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S. (2005). Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B Biointerfaces 45:167-173 (Pubitemid 41415646)
6. Joshi M, Pathak S, Sharma S, Patravale V. (2008). Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: Nanoject. Int J Pharm 364:119-126
7. Joshi M, Patravale V. (2008). Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm 346:124-132 (Pubitemid 350110507)
8. Li CY, Wang EQ, Cheng Y, Bao JK. (2011). Oridonin: An active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer therapeutics. Int J Biochem Cell Biol 43:701-704
9. Li F, Weng Y, Wang L, He H, Yang J, Tang X. (2010). The efficacy and safety of bufadienolides-loaded nanostructured lipid carriers. Int J Pharm 393:203-211
10. Li S, Liu Y, Liu T, Zhao L, Zhao J, Feng N. (2011). Development and in-vivo assessment of the bioavailability of oridonin solid dispersions by the gas anti-solvent technique. Int J Pharm 411:172-177
11. Lin XH, Li XW, Zheng LQ, Yu L, Zhang QQ, Liu WC. (2007). Preparation and characterization of monocaprate nanostructured lipid carriers. Colloid Surface A. 311:106-111 (Pubitemid 350026290)
12. Lou H, Gao L, Wei X, Zhang Z, Zheng D, Zhang D, Zhang X, Li Y, Zhang Q. (2011). Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor bearing mice. Colloids Surf B Biointerfaces 87:319-325
13. Lou H, Zhang X, Gao L, Feng F, Wang J, Wei X, Yu Z, Zhang D, Zhang Q. (2009). In vitro and in vivo antitumor activity of oridonin nanosuspension. Int J Pharm 379:181-186
14. Manjunath K, Venkateswarlu V. (2005). Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release 107:215-228 (Pubitemid 41319672)
15. zur Mühlen A, Schwarz C, Mehnert W. (1998). Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm 45:149-155 (Pubitemid 28167741)
16. Müller RH, Jacobs C. (2002). Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int J Pharm 237:151-161 (Pubitemid 34310488)
17. Müller RH, Radtke M, Wissing SA. (2002a). Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 242:121-128
18. Müller RH, Radtke M, Wissing SA. (2002b). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 54 Suppl 1:S131-S155 (Pubitemid 35379959)
19. Obeidat WM, Schwabe K, Müller RH, Keck CM. (2010). Preservation of nanostructured lipid carriers (NLC). Eur J Pharm Biopharm 76:56-67
20. Ren KK, Wang HZ, Xie LP, Chen DW, Liu X, Sun J, Nie YC, Zhang RQ. (2006). The effects of oridonin on cell growth, cell cycle, cell migration and differentiation in melanoma cells. J Ethnopharmacol 103:176-180 (Pubitemid 41796914)
21. Tiwari R, Pathak K. (2011). Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm 415:232-243
22. Wang H, Ye Y, Pan SY, Zhu GY, Li YW, Fong DW, Yu ZL. (2011). Proteomic identification of proteins involved in the anticancer activities of oridonin in HepG2 cells. Phytomedicine 18:163-169
23. Xing J, Zhang D, Tan T. (2007). Studies on the oridonin-loaded poly(D,Llactic acid) nanoparticles in vitro and in vivo. Int J Biol Macromol 40:153-158 (Pubitemid 46027243)
24. Zhang P, Liu Y, Feng N, Xu J. (2008). Preparation and evaluation of selfmicroemulsifying drug delivery system of oridonin. Int J Pharm 355:269-276
25. Zhang XY, Liu JP, Qiao H, Liu H, Ni JM, Zhang WL, Shi YB. (2010). Formulation optimization of dihydroartemisinin nanostructured lipid carrier using response surface methodology. Powder Technol 197:120-128.